Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing trib1/hdac activity

HIGHLIGHTS

  • who: Lihui Wang from the DepartmentPharmaceutical University Army, Wuhan, China have published the research work: Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity, in the Journal: (JOURNAL)
  • how: Realtime cell analysis data indicated that only treatment with CDDP promoted cell migration as compared with DMSO control . ChIP assay and real-time PCR data indicated that CDDP-pretreated NCI-H460 cells exhibited a reduced binding ability of p53 to p21 promoter and displayed decreasing expression of p21 at mRNA level which Cell Death and . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?